FDA Dermal Fillers Panel Calls For Larger Clinical Trials Focused On Safety
This article was originally published in The Gray Sheet
FDA's General and Plastic Surgery Devices advisory panel called for larger, safety-focused pre-market clinical trials for future aesthetic facial dermal filler products
You may also be interested in...
Signs point to a suppressed market for all aesthetics products for at least the remainder of 2009, but there's some evidence that dermal fillers have escaped the worst effects of the economic downturn. The American Society of Plastic Surgeons reports that while there was a 5% decrease in facelifts in 2008, the use of hyaluronic acid fillers was up by 6%, although dermal filler sales started to take a hit in the final quarter of the year.
New additions to Mentor's fledgling Prevelle dermal filler portfolio in the U.S. will help grow its facial aesthetic product revenue in the next several years, the company said during a Nov. 5 second-quarter earnings call
As FDA decision on Alzheimer’s product approaches, new paper outlines Lilly’s arguments for unfettered Medicare coverage for donanemab once it is approved.